BR9907964A - Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos - Google Patents

Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos

Info

Publication number
BR9907964A
BR9907964A BR9907964-0A BR9907964A BR9907964A BR 9907964 A BR9907964 A BR 9907964A BR 9907964 A BR9907964 A BR 9907964A BR 9907964 A BR9907964 A BR 9907964A
Authority
BR
Brazil
Prior art keywords
sym
models
rlla
crystals
structures
Prior art date
Application number
BR9907964-0A
Other languages
English (en)
Inventor
Mark P Hogarth
Maree S Powell
Ian F C Mckenzie
Kelly F Maxwell
Thomas P J Garret
Barry R Matthews
Thomas D Mccarthy
Geoffrey A Pietersz
Jonathan B Baell
Vidana Epa
Original Assignee
Ilexus Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilexus Pty Limited filed Critical Ilexus Pty Limited
Publication of BR9907964A publication Critical patent/BR9907964A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Processing Or Creating Images (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<B>"ESTRUTURAS TRIDIMENSIONAIS E MODELOS DE RECEPTORES Fc E USOS DOS MESMOS"<D> - São apresentados cristais, proteínas Fc<sym>Rlla de estrutura de cristal, coordenadas tridimensionais de proteínas Fc<sym>Rlla, e estruturas e modelos derivados da estrutura de Fc<sym>Rlla, são também apresentados cristais de proteína Fc<sym>Rl e coordenadas tridimensionais de monómeros e dímeros de proteína Fc<sym>Rl derivados da estrutura de Fc<sym>Rlla, são também apresentadas coordenadas tridimensionais de proteínas Fc<sym>Rllb e modelos de Fc<sym>Rllb derivados da estrutura de Fc<sym>Rlla; a presente invenção também inclui métodos para produzir estes cristais, estruturas de cristal e modelos; os usos destes cristais, estruturas de cristal e modelos são também apresentados, incluindo desenvolvimento de droga baseado na estrutura e composições terapêuticas.
BR9907964-0A 1998-02-06 1999-02-04 Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos BR9907964A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7397298P 1998-02-06 1998-02-06
US9999498P 1998-09-11 1998-09-11
PCT/IB1999/000367 WO1999040117A1 (en) 1998-02-06 1999-02-04 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR9907964A true BR9907964A (pt) 2000-10-17

Family

ID=26755120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907964-0A BR9907964A (pt) 1998-02-06 1999-02-04 Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos

Country Status (16)

Country Link
US (2) US6675105B2 (pt)
EP (1) EP1053255A4 (pt)
JP (1) JP2004510681A (pt)
KR (1) KR20010024899A (pt)
CN (1) CN1291198A (pt)
AP (1) AP2000001876A0 (pt)
AU (1) AU759378B2 (pt)
BR (1) BR9907964A (pt)
CA (1) CA2316860A1 (pt)
EA (1) EA200000746A1 (pt)
IL (1) IL137583A0 (pt)
NO (1) NO20003964L (pt)
NZ (1) NZ505914A (pt)
PL (1) PL342297A1 (pt)
TR (1) TR200002271T2 (pt)
WO (1) WO1999040117A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553809B2 (en) 1998-02-06 2009-06-30 Ilexus Pty Limited Fc receptor modulators and uses thereof
JP2002524504A (ja) 1998-09-11 2002-08-06 イレクサス・ピーティーワイ・リミテッド Ｆｃ受容体調節剤およびそれの使用
CA2349410A1 (en) * 1998-11-05 2000-05-11 Heska Corporation Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US7912689B1 (en) 1999-02-11 2011-03-22 Cambridgesoft Corporation Enhancing structure diagram generation through use of symmetry
US7295931B1 (en) 1999-02-18 2007-11-13 Cambridgesoft Corporation Deriving fixed bond information
US6850876B1 (en) * 1999-05-04 2005-02-01 Smithkline Beecham Corporation Cell based binning methods and cell coverage system for molecule selection
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
US7356419B1 (en) 2000-05-05 2008-04-08 Cambridgesoft Corporation Deriving product information
US7272509B1 (en) * 2000-05-05 2007-09-18 Cambridgesoft Corporation Managing product information
IL144082A0 (en) * 2000-07-14 2002-05-23 Medical Res Council Crystal structure of antibiotics bound to the 30s ribosome and its use
GB0029871D0 (en) * 2000-07-14 2001-01-24 Medical Res Council Crystal structure (V)
EP1201681A1 (en) 2000-10-30 2002-05-02 Millennium Pharmaceuticals, Inc. "Fail" molecules and uses thereof
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
IL158488A0 (en) * 2001-04-20 2004-05-12 Sinai School Medicine Tir3 a novel taste receptor
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
EP1495432A2 (en) * 2002-04-10 2005-01-12 TransTech Pharma Inc. System and method for data analysis, manipulation, and visualization
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
BRPI0406724A (pt) 2003-01-13 2005-12-20 Macrogenics Inc Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada
US7499847B2 (en) * 2003-05-26 2009-03-03 Biotie Therapies Corporation Crystalline VAP-1 and uses thereof
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
WO2005075512A1 (en) * 2004-02-10 2005-08-18 The Austin Research Institute Crystal structures and models for fc receptors and uses thereof in the design or identification of fc receptor modulator compounds
WO2006133486A1 (en) * 2005-06-14 2006-12-21 The Macfarlane Burnet Institute For Medical Research And Public Health Limited CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTOR:Fc COMPLEXES AND USES THEREOF
US8603950B2 (en) 2007-02-20 2013-12-10 Anaptysbio, Inc. Methods of generating libraries and uses thereof
AU2011248243B2 (en) * 2010-05-03 2015-03-26 Perkinelmer Informatics, Inc. Method and apparatus for processing documents to identify chemical structures
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
US9977876B2 (en) 2012-02-24 2018-05-22 Perkinelmer Informatics, Inc. Systems, methods, and apparatus for drawing chemical structures using touch and gestures
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
US9535583B2 (en) 2012-12-13 2017-01-03 Perkinelmer Informatics, Inc. Draw-ahead feature for chemical structure drawing applications
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US8854361B1 (en) 2013-03-13 2014-10-07 Cambridgesoft Corporation Visually augmenting a graphical rendering of a chemical structure representation or biological sequence representation with multi-dimensional information
US10412131B2 (en) 2013-03-13 2019-09-10 Perkinelmer Informatics, Inc. Systems and methods for gesture-based sharing of data between separate electronic devices
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
US9430127B2 (en) 2013-05-08 2016-08-30 Cambridgesoft Corporation Systems and methods for providing feedback cues for touch screen interface interaction with chemical and biological structure drawing applications
US9751294B2 (en) 2013-05-09 2017-09-05 Perkinelmer Informatics, Inc. Systems and methods for translating three dimensional graphic molecular models to computer aided design format
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
EP3590056A1 (en) 2017-03-03 2020-01-08 Perkinelmer Informatics, Inc. Systems and methods for searching and indexing documents comprising chemical information
KR101986252B1 (ko) * 2017-09-15 2019-06-05 국민대학교 산학협력단 Fc 감마 수용체 변이체 MG2A28
KR101987268B1 (ko) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc 감마 수용체 변이체 MG2A45
CN111183150B (zh) * 2017-09-15 2024-04-02 国民大学校产学协力团 Fcγ受体突变体
KR101987292B1 (ko) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc 감마 수용체 변이체 MG2B45.1
KR101987279B1 (ko) * 2017-10-12 2019-06-10 국민대학교 산학협력단 Fc 감마 수용체 변이체 MG2A45.1
KR101986250B1 (ko) * 2017-09-15 2019-06-05 국민대학교 산학협력단 Fc 감마 수용체 변이체 SH2A40
KR101987272B1 (ko) * 2017-09-15 2019-06-10 국민대학교 산학협력단 Fc 감마 수용체 변이체 MG2A28.1
WO2019183437A1 (en) * 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
CN115035947B (zh) * 2022-06-10 2023-03-10 水木未来(北京)科技有限公司 蛋白质结构建模方法及装置、电子设备和存储介质

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JP2002524504A (ja) * 1998-09-11 2002-08-06 イレクサス・ピーティーワイ・リミテッド Ｆｃ受容体調節剤およびそれの使用
WO2002016311A1 (fr) * 2000-08-22 2002-02-28 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif

Also Published As

Publication number Publication date
JP2004510681A (ja) 2004-04-08
IL137583A0 (en) 2001-07-24
EP1053255A1 (en) 2000-11-22
WO1999040117A1 (en) 1999-08-12
AU2438299A (en) 1999-08-23
KR20010024899A (ko) 2001-03-26
US20020107359A1 (en) 2002-08-08
NO20003964D0 (no) 2000-08-04
CN1291198A (zh) 2001-04-11
EA200000746A1 (ru) 2001-04-23
PL342297A1 (en) 2001-06-04
EP1053255A4 (en) 2003-01-02
CA2316860A1 (en) 1999-08-12
NZ505914A (en) 2004-03-26
NO20003964L (no) 2000-10-04
AP2000001876A0 (en) 2000-09-30
TR200002271T2 (tr) 2000-11-21
US20040054480A1 (en) 2004-03-18
AU759378B2 (en) 2003-04-10
US6675105B2 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
BR9907964A (pt) Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos
DE3676670D1 (de) Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
HUP0003513A2 (hu) Apoptózist indukáló monoklonális antitest
DE69925374D1 (de) Spinales osteosynthesesystem mit verbesserter stabilität
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
DK0806952T3 (da) Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
ATE320226T1 (de) Chirurgische navigationsanordnung einschliesslich referenz- und ortungssystemen
DE69638162D1 (de) Bindegewebs wachstumsfaktor (ctgf)
DE69638023D1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
HUP9902429A2 (hu) TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
HUP0203935A2 (hu) Az endotelin aktivitását módosító szulfonamidok és származékaik, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0100535A2 (hu) Módosított hidrofóbitású proteinkészítmények és eljárások előállításukra
DK58387D0 (da) Farmaceutiske praeparatformer til stabilisering af interferon-alfa, deres anvendelse og fremgangsmaade til deres fremstilling
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
HUP0002427A2 (hu) Leptin mint tumorsejt proliferációt gátló hatóanyag és alkalmazása
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
NO983799L (no) Hybride proteiner som danner heterodimerer
GB9311454D0 (en) Pharmaceutical compositions
DE69528170T2 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
JPS52128205A (en) Prophylactic and therapeutic drugs for cerebro-vascular contraction
PT871757E (pt) Vectores virais condicionalmente replicantes e sua utilizacao
DE69718146T2 (de) At1 rezeptor antagonist zur anregung von apoptosis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A E 12A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.

B15K Others concerning applications: alteration of classification

Ipc: C07K 14/735 (2006.01), A61K 38/00 (2006.0